A new oral antiviral drug candidate has been developed to treat diseases caused by orthoparamyxoviruses, such as measles and croup syndrome, according to research published by researchers at Georgia State University’s Center for Translational Antiviral Research.
Research published in journals scientific progress We identified GHP-88310, a clinical candidate for improved orthoparamyxovirus disease management that is urgently needed in rodent and non-rodent infected animal models. Orthoparamyxoviruses, such as human parainfluenza virus, measles virus, and emerging henipavirus, pose a significant threat to human health.
We developed GHP-88310 to treat orthoparamyxovirus infections. GHP-88310 is the most promising inhibitor of this virus family that we have discovered over many years of research. ”
Carolyn Lieber, Senior Postdoctoral Researcher, Center for Translational Antiviral Research, Georgia State Biomedical Sciences Institute, lead study author
In this study, researchers initially focused on human parainfluenza virus type 3 as the primary clinical indication for drug development. The elderly, immunocompromised individuals, and adult hematopoietic stem cell transplant patients are at high risk for life-threatening parainfluenza virus pneumonia, with an estimated 3 million patients requiring treatment annually in the United States. There are no vaccines or treatments available to manage this disease. A secondary indication for GHP-88310 is measles, which has seen a resurgence in recent months, with large outbreaks occurring in large areas of the United States, Mexico, and Canada.
“Reemerging orthoparamyxoviruses, such as parainfluenza virus and measles virus, are a major threat to vulnerable populations such as children and the immunocompromised,” said Richard Premper, director of the Center for Translational Antiviral Research and senior author of the study. “We specifically designed this drug discovery program to address the medical needs of these patient groups.”
To identify GHP-88310, the research team initiated a large-scale high-throughput drug screening campaign to identify and optimize early generation leads and characterize GHP-88310 in various animal models and human airway organoid cultures.
Interesting features of GHP-88310 include that the compound is highly effective against a wide range of orthoparamyxoviral diseases when taken orally once daily, is well tolerated at very high concentrations in rodents and higher mammals, and has a high barrier to deviation from inhibition of the virus in animals.
“High efficacy and good tolerability ensure a very wide margin of safety, which is essential for drug candidates developed for the treatment of highly vulnerable patient groups and children,” said Premper.
Other authors of the study include Josef D. Wolf, Jeong-Joong Yoon, Claire E. Ruckel, Alexander I. Leach, Lauren A. Harrison, and Robert M. Cox of the Georgia State Biomedical Research Institute Translational Antiviral Research Center. Muganthan Govindarajan, Zachary M. Stitcher, Amalia Ann Crews, Megan K. Andrews, Rebecca E. Krueger, George R. Painter, and Michael G. Nachus of Emory University’s Emory Drug Discovery Institute; Daria Vischenska and Alexander L. Greninger of the University of Washington Medical Center;
This study was funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
sauce:
Reference magazines:
Lieber, C.M.; others. (2026). Development candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models. Science progresses. Doi: 10.1126/sciadv.aef1594. https://www.science.org/doi/10.1126/sciadv.aef1594
